Hepatitis B News and Research

Latest Hepatitis B News and Research

Govs brace for impact of scheduled cuts in home states

The nation's governors met in Washington over the weekend, and among their hottest topics: a White House warning regarding the state-by-state impact of sequestration, which is scheduled to kick in March 1.

26 Feb 2013

Wnt-induced Lgr5 expression marks stem cell production in the liver

For decades scientists around the world have attempted to regenerate primary liver cells known as hepatocytes because of their numerous biomedical applications, including hepatitis research, drug metabolism and toxicity studies, as well as transplantation for cirrhosis and other chronic liver conditions. But no lab in the world has been successful in identifying and growing liver stem cells in culture -- using any available technique - until now.

26 Feb 2013

Janssen submits simeprevir regulatory application in Japan to treat HCV

Medivir AB today announced that its partner Janssen now has submitted a regulatory application to the Japanese Ministry of Health & Welfare authorities seeking approval for simeprevir, administered with pegylated interferon (Peg-IFN) and ribavirin (RBV) for the treatment of genotype 1 chronic hepatitis C patients who are treatment naïve, prior non responders or relapsed following treatment with Peg-IFN with or without RBV.

22 Feb 2013

EASL unveils new publication - The burden of liver disease in Europe

Major progress has been made in the past 30 years in the knowledge and management of liver disease, yet approximately 29 million Europeans still suffer from a chronic liver condition. The European Association for the Study of the Liver (EASL) today unveiled its new publication The burden of liver disease in Europe: a review of available epidemiological data.

22 Feb 2013

Daclatasvir has two primary modes of action against HCV

A study by researchers from Los Alamos National Laboratory and a multinational team reveals how daclatasvir, a direct-acting antiviral agent in development for the treatment of hepatitis C virus (HCV), targets one of its proteins and causes the fastest viral decline ever seen with anti-HCV drugs - within 12 hours of treatment.

21 Feb 2013

UCB seeks FDA and EMA marketing authorization for Cimzia to treat active psoriatic arthritis

UCB announced today two new regulatory filings with the US Food and Drug Administration (FDA) and with the European Medicines Agency (EMA) to extend the marketing authorization for Cimzia (certolizumab pegol) for the treatment of adult patients with active psoriatic arthritis (PsA) and for adult patients with active axial spondyloarthritis (axSpA).

20 Feb 2013

Study may help design better DAA drug cocktails to treat HCV

Hepatitis C virus (HCV) infection affects about 4 million in the United States and is the primary cause of liver cirrhosis and liver cancer. Current therapy against HCV is suboptimal. Daclatasvir, a direct acting antiviral (DAA) agent in development for the treatment of HCV, targets one of the HCV proteins (i.e., NS5A) and causes the fastest viral decline (within 12 hours of treatment) ever seen with anti-HCV drugs.

20 Feb 2013

Gilead to resolve Viread patent litigation case with Teva

Gilead Sciences, Inc. today announced that Gilead and Teva Pharmaceuticals have reached an agreement in principle to settle the ongoing patent litigation concerning the patents protecting Viread (tenofovir disoproxil fumarate), a treatment for HIV infection and chronic hepatitis B. Under the terms of the settlement, Teva will be allowed to launch a generic version of Viread on December 15, 2017.

20 Feb 2013

New coronavirus could potentially be treated with immunotherapy

The new coronavirus that has emerged in the Middle East is well-adapted to infecting humans but could potentially be treated with immunotherapy, according to a study to be published on February 19 in mBio-, the online open-access journal of the American Society for Microbiology.

20 Feb 2013

SARS-linked virus well adapted to infect humans, could be treated with drugs to boost immune system, study shows

"A new virus that emerged in the Middle East last year and has killed five people is well adapted to infecting humans but could potentially be treated with drugs that boost the immune system, scientists said on Tuesday," Reuters reports, noting, "The virus, called novel coronavirus or NCoV, is from the same family as the common cold and as SARS, or Severe Acute Respiratory Syndrome."

19 Feb 2013

BioCryst fourth quarter revenues decrease to $4.1 million

BioCryst Pharmaceuticals, Inc. announced financial results for the fourth quarter and full year ended December 31, 2012.

19 Feb 2013

New lab at Diamond to help scientists delve into inner workings of pathogens

The UK's national synchrotron facility, Diamond Light Source, is now the first and only place in Europe where pathogens requiring Containment Level 3 - including serious viruses such as those responsible for AIDS, Hepatitis and some types of flu - can be analysed at atomic and molecular level using synchrotron light.

18 Feb 2013

Researchers describe novel antiviral property of cholesterol-25-hydroxylase

A team of UCLA-led researchers has identified a protein with broad virus-fighting properties that potentially could be used as a weapon against deadly human pathogenic viruses such as HIV, Ebola, Rift Valley Fever, Nipah and others designated "priority pathogens" for national biosecurity purposes by the National Institute of Allergy and Infectious Disease.

13 Feb 2013

DNAzymes and gold nanoparticles used to detect infectious diseases

Infectious diseases such as malaria and syphilis can be diagnosed rapidly and reliably in the field by using a simple test developed by Canadian scientists. The test is based on the use of DNAzymes and gold nanoparticles. As the researchers report in the journal Angewandte Chemie, their test allows for the sensitive detection of bacteria, viruses, and parasites.

12 Feb 2013

Social networking sites could effectively help prevent HIV infection among at-risk groups

Facebook and other social networking technologies could serve as effective tools for preventing HIV infection among at-risk groups, new UCLA research suggests.

9 Feb 2013

Ongoing conflict aggravating health of Syrians, WHO warns

The WHO on Tuesday "warned that the ongoing conflict in Syria, which will soon enter its third year, will lead to a sharp spike in the number of people needing urgent aid, including food, clean water and vital medical services," the U.N. News Centre reports.

9 Feb 2013

Gilead Sciences fourth quarter total revenues increase 18% to $2.59 billion

Gilead Sciences, Inc. announced today its results of operations for the fourth quarter and full year 2012.

5 Feb 2013

Topline results from Gilead’s FISSION and NEUTRINO Phase 3 studies on HCV infection

Gilead Sciences today announced topline results from two Phase 3 studies, FISSION and NEUTRINO, evaluating a 12-week course of the once-daily nucleotide sofosbuvir in combination with ribavirin (FISSION) and in combination with ribavirin and pegylated interferon (NEUTRINO) among treatment-naïve patients with chronic hepatitis C virus (HCV) infection.

5 Feb 2013

Interferon retreatment warning in HCV

Hepatitis C virus patients who do not respond to interferon should not receive further treatment with the drug, say the authors of a new Cochrane review.

4 Feb 2013

Epidemiology model supports 20:80 transmission rule in HCV

A new hepatitis C virus transmission model combining genetic and epidemiologic data reveals that the majority of transmission of the virus is by a minority of intravenous drug users.

4 Feb 2013